Pfizer

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatment approaches. This enables patients to access effective and safe treatments for neurological, inflammatory, and oncological conditions.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

RNT Health Insights develops an AI-assisted software as a medical device (SaMD) solution for early gastric cancer detection. This technology, granted FDA Breakthrough Device Designation, improves efficiency and accuracy in real-time during endoscopic procedures, with preclinical validation showing 96% accuracy in detecting lesions indicative of gastric cancer.

Enara Bio Limited is a biotechnology company based in Oxford, United Kingdom, specializing in the development of vaccines and immunotherapies for cancer treatment and prevention. Founded in 2016 and previously known as ErVaxx Limited, the company focuses on creating targeted cancer immunotherapies by exploring novel antigens derived from endogenous retroviral DNA sequences. Enara Bio's technology platform enables the identification and assessment of tumor specificity and immunogenic potential, facilitating improved strategies for combating various cancers. Through its innovative approach, the company aims to provide effective therapeutic options for a broad patient population.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

CytoReason is a biotechnology company that specializes in developing a cell-centered computational model of the human body to analyze complex biological data. By collecting proprietary information from pharmaceutical companies, CytoReason simulates human diseases at both the tissue and cellular levels. Its advanced platform utilizes machine learning to reconstruct cellular information from bulk tissue, training an immune-specific engine and integrating multi-omics data. This approach enables pharmaceutical and biotech companies to gain mechanistic insights into the immune system, facilitating the discovery and development of targeted therapies. The company's innovative technology helps shorten clinical trial phases, reduce development costs, and increase the likelihood of successful regulatory approval.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Urban Health Plan, Inc. is a health center located in the Bronx, New York, serving the communities of Hunts Point, Mott Haven, and Morrisania. Established in 1974, it specializes in delivering both primary and specialty healthcare services. The organization offers a wide range of primary care options, including adolescent and adult medicine, dentistry, family planning, and pediatrics. Specialty services encompass areas such as cardiology, neurology, psychiatry, and pulmonary care, among others. Additionally, Urban Health Plan provides ancillary services like audiology, nutrition, physical therapy, and social services, as well as various diagnostic capabilities including digital radiology and laboratory testing. The center also emphasizes support services through programs focused on asthma management, diabetes care, health education, and health insurance enrollment. Furthermore, Urban Health Plan integrates telehealth services to enhance access to care for its patients.

Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies to mimic T-cells, which are essential components of the immune system, aiming to enhance the quality of life for cancer patients. Their next-generation immunotherapies are designed to target previously unreachable cancer cell proteins with high precision, offering an efficient and selective approach to cancer treatment. By unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics seeks to dramatically expand the capabilities of antibody therapy across various cancer types, ultimately improving patient outcomes.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

Caribou Biosciences develops cellular engineering solutions based on CRISPR technologies, offering a gene editing platform with applications in human therapeutics, disease modeling, genomics research, and agricultural biotechnology.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Promise Bio is a biotechnology company specializing in precision medicine for autoimmune diseases. It leverages epiproteomic analysis, a cutting-edge technique that examines protein modifications, using a cloud-based AI platform to interpret standard mass-spectrometry data. This innovative approach aims to uncover disease mechanisms and facilitate personalized treatment plans, ultimately improving patient care and affordability.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

VitaDAO is a decentralized collective funding organization focused on early-stage longevity research. Its mission is to extend human lifespan by supporting research, financing, and commercialization of longevity therapeutics through open and democratic participation. The organization nurtures and develops the intellectual property, licenses, and data sets arising from the projects it backs and encourages member contributions of work or intellectual property. Founded in 2021 and based in Ottawa, Canada, VitaDAO coordinates resources and expertise across its community to advance longevity science and related ventures.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Founded in 2015, Carrick Therapeutics is a biopharmaceutical company based in Dublin, Ireland. It specializes in developing innovative cancer therapeutics that target molecular pathways driving aggressive and resistant forms of cancer, aiming to transform cancer treatment.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Nucleome Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2019. The company focuses on decoding the "dark matter" of the human genome, which comprises over 95% of disease-linked genetic variants that have not yet been fully explored. By leveraging a unique platform that creates high-resolution three-dimensional genome structure maps and employs machine learning techniques, Nucleome aims to link these genetic variants to gene functions and map disease pathways. This innovative approach facilitates the functional validation of variants in primary cell types, enabling the discovery and development of novel therapeutics. Initially concentrating on lymphocytes and autoimmune diseases, Nucleome Therapeutics seeks to establish a robust pipeline of drug assets along with corresponding biomarkers to improve patient outcomes through genetically guided therapeutics.

CytoReason is a biotechnology company that specializes in developing a cell-centered computational model of the human body to analyze complex biological data. By collecting proprietary information from pharmaceutical companies, CytoReason simulates human diseases at both the tissue and cellular levels. Its advanced platform utilizes machine learning to reconstruct cellular information from bulk tissue, training an immune-specific engine and integrating multi-omics data. This approach enables pharmaceutical and biotech companies to gain mechanistic insights into the immune system, facilitating the discovery and development of targeted therapies. The company's innovative technology helps shorten clinical trial phases, reduce development costs, and increase the likelihood of successful regulatory approval.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

VitaDAO is a decentralized collective funding organization focused on early-stage longevity research. Its mission is to extend human lifespan by supporting research, financing, and commercialization of longevity therapeutics through open and democratic participation. The organization nurtures and develops the intellectual property, licenses, and data sets arising from the projects it backs and encourages member contributions of work or intellectual property. Founded in 2021 and based in Ottawa, Canada, VitaDAO coordinates resources and expertise across its community to advance longevity science and related ventures.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for underserved patient communities, particularly those affected by blood disorders. The company is advancing its lead product candidate, Oxbryta (voxelotor), which is an oral, once-daily therapy designed for the treatment of sickle cell disease (SCD). Oxbryta has completed Phase III clinical trials in adult and adolescent patients and is currently being evaluated for safety and pharmacokinetics in a Phase IIa trial involving pediatric patients. In addition to its efforts in SCD, Global Blood Therapeutics is engaged in research and development for other blood-related conditions, including hereditary angioedema, and holds licensed rights to its product candidates in multiple regions, including the United States and Europe.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies to combat cancer by harnessing the innate immune system. The company is pioneering a platform dedicated to creating next-generation macrophage immunotherapies, which aim to activate macrophages and immune phagocytes to effectively target and eliminate tumors. By researching and targeting specific signals on both cancer cells and macrophages, DEM BioPharma seeks to provide healthcare researchers with advanced treatment options that enhance the body's ability to fight cancer.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapeutics targeting cancer's underlying biological pathways. Its pipeline includes two lead product candidates: ZN-c5 for advanced estrogen receptor-positive breast cancer, and ZN-c3 for advanced solid tumors and platinum-resistant ovarian cancer.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

ResApp Health Limited is a developer of digital healthcare solutions focused on enabling doctors and patients to diagnose and manage respiratory diseases. Founded in 2014 and headquartered in Brisbane, Australia, the company offers ResAppDx, a smartphone-based diagnostic test for acute respiratory diseases, suitable for telehealth, emergency departments, and primary care settings. Additionally, it provides SleepCheck, a direct-to-consumer application for self-assessing sleep apnoea in multiple countries. ResApp's technology leverages sound analysis to identify various respiratory conditions, including pneumonia, bronchiolitis, and asthma. The company is committed to creating user-friendly, clinically validated, and regulatory-approved diagnostic tools that integrate seamlessly into existing telehealth frameworks, enhancing accessibility for both healthcare providers and patients. ResApp Health was previously known as Narhex Life Sciences Limited.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Triana Biomedicines develops a molecular glue discovery platform targeting challenging disease targets. Its drug discovery engine combines high-resolution structural insights, advanced computational tools, and proprietary chemical libraries.

National Eczema Association is the 501(c)(3) non-profit, US patient advocacy organization serving people affected by eczema. NEA is the driving force for an eczema community fueled by knowledge, strengthened through collective action, and propelled by the promise of a better future.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

MindImmune Therapeutics is a pharmaceutical company that develops antibody-based therapies targeting the immune system to treat diseases of the central nervous system. Its programs aim to address neuroinflammation associated with brain disorders such as Alzheimer's disease, Huntington's disease, pain, and psychiatric conditions. The company emphasizes the role of immune dysfunction in CNS pathology and seeks to inhibit peripheral innate immune responses to produce therapeutic effects. Based in Kingston, Rhode Island, MindImmune pursues collaborations with neuroscience research institutions to advance its drug development initiatives.

Founded in 2017, Anaveon develops biologics that modulate cytokine function to provide therapeutic benefits for cancer patients and those with immune-related disorders. The company focuses on IL-2 complexes that selectively enhance effector T cell functions, acting as effective immune adjuvants.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing innovative medicines for various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. Founded in 1997, the company focuses on pharmacology and pharmacokinetics, advancing several investigational drugs through clinical trials. Notable candidates include Etrasimod, which is in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn’s disease, and Olorinab, currently in Phase IIb trials for abdominal pain linked to irritable bowel syndrome. Additionally, Arena is developing ralinepag for pulmonary arterial hypertension and APD418 for acute heart failure. The company has formed collaborations with several organizations, including United Therapeutics and Eisai, to enhance its research and expand its market presence. Arena Pharmaceuticals also has a marketed product, lorcaserin, approved for weight management, further demonstrating its commitment to addressing critical health challenges through innovative therapies.

Kestrel Therapeutics is a medical research and development company focused on oncology that develops treatment solutions for cancers driven by RAS mutations. It designs molecules active across RAS isoforms, mutations, and tumor histologies, aiming to deliver new therapies that target the frequently mutated RAS oncogenic pathway.

PATH is an international nonprofit organization that transforms global health through innovation. It takes an entrepreneurial approach to developing and delivering high‑impact, low‑cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through its work in more than 70 countries, PATH and its partners empower people to achieve their full potential.

CARE is a well-known international humanitarian organization. They bring about long-lasting change in some of the world's poorest areas, and they pay particular attention to assisting impoverished women because, with the right tools, they have the capacity to free whole families and entire communities from poverty.

The International Rescue Committee (IRC) is an independent non-profit organization based in New York City, founded in 1933. It serves as a global leader in providing emergency relief and rehabilitation to individuals affected by conflict and oppression. The IRC responds to humanitarian crises by offering life-saving assistance to refugees and displaced persons, helping them survive and rebuild their lives. Its services encompass a wide range of areas, including education, healthcare, women's empowerment, child welfare, disaster response, and preparedness. Additionally, the organization focuses on refugee resettlement, governance, and the protection of human rights, as well as ensuring access to water and sanitation. Through its comprehensive approach, the IRC aims to support vulnerable populations in overcoming adversity and achieving sustainable development.

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company based in Mississauga, Canada, that specializes in developing therapies for cancer treatment. The company focuses on harnessing the immune system to combat malignancies through innovative protein therapeutics. Its lead program, TTI-621, is a SIRPaFc fusion protein currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, solid tumors, and mycosis fungoides. Additionally, Trillium is advancing TTI-622, another SIRPaFc protein in Phase I trials, while also exploring TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase. Originally founded in 2004, the company has undergone several name changes, reflecting its evolving focus within the biopharmaceutical sector.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

LianBio is a biopharmaceutical company founded in 2019, headquartered in Shanghai, China, with an additional office in Princeton, New Jersey. The company is dedicated to the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as addressing other unmet medical needs in Greater China and major Asian markets. LianBio focuses on in-licensing assets and collaborates with leading partners to enhance its pipeline, which includes clinically validated product candidates across various therapeutic areas such as cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory indications. The company aims to accelerate the availability of innovative medicines to improve patient outcomes through a science-driven approach.

Arixa Pharmaceuticals, Inc. is a biotechnology company focused on developing oral antibiotics to combat drug-resistant Gram-negative infections. Founded in 2016 and based in Palo Alto, California, the company is advancing its lead product, ARX-1796, an oral prodrug of Avibactam, a broad-spectrum beta-lactamase inhibitor approved by the FDA. Arixa utilizes a unique prodrug chemistry technology platform that transforms intravenous-only antimicrobial agents into formulations suitable for oral administration. This innovation addresses significant medicinal chemistry challenges associated with prodrug development in this class of compounds. Arixa aims to provide effective treatment options for patients suffering from bacterial infections, while also securing broad patent protection for its proprietary formulations.

Palleon Pharmaceuticals is a biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer. Its platform integrates insights from glycoscience and human immunology, enabling it to create novel therapies targeting multiple immune cell types.

Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company based in Mississauga, Canada, that specializes in developing therapies for cancer treatment. The company focuses on harnessing the immune system to combat malignancies through innovative protein therapeutics. Its lead program, TTI-621, is a SIRPaFc fusion protein currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, solid tumors, and mycosis fungoides. Additionally, Trillium is advancing TTI-622, another SIRPaFc protein in Phase I trials, while also exploring TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase. Originally founded in 2004, the company has undergone several name changes, reflecting its evolving focus within the biopharmaceutical sector.

ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Bolt Biotherapeutics is a biotechnology company developing cancer immunotherapies based on the Boltbody platform, which links tumor-targeting antibodies to immune-stimulating payloads to activate innate and adaptive immune responses against solid tumors. The platform aims to transform non-responsive, or cold, tumors into immunologically active ones by delivering immune stimulants at the tumor site. The company’s pipeline includes BDC-1001 as a monotherapy for HER2-expressing solid tumors, with additional candidates such as BDC-3042 and Next-Gen ISAC designed to broaden its immuno-oncology program. Bolt Biotherapeutics focuses on myeloid biology and tumor-targeted therapies to leverage immune mechanisms for cancer treatment.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

FoRx Therapeutics is a biotechnology company focused on developing cancer therapies by targeting DNA replication stress. It seeks to drug key molecular targets involved in replication stress to create targeted anticancer drugs. Founded in 2019 and based in Basel, Switzerland, the company emphasizes a novel approach by targeting DNA replication stress pathways activated in cancer cells, with the goal of delivering first-in-class therapies that address the underlying mechanisms of tumor growth.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.

Montis Biosciences is a biotechnology company founded in 2020 and based in Meise, Belgium. The company focuses on developing innovative immune-oncology therapeutics that address the intersection of vascular dysfunction and immune suppression in the treatment of solid tumors. Montis Biosciences has created a proprietary target screening and assay platform aimed at modulating the interactions between tumor endothelial cells and perivascular macrophages. This research provides valuable insights into the cellular dynamics of these interactions, enabling the development of novel therapeutic strategies to enhance immune responses against various tumors.